Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
Date:10/21/2008

nges in pricing and the competitive environment, (2) fluctuations in foreign currency exchange rates, (3) dependence on uninterrupted manufacturing operations, (4) changes in the regulatory environment in which the Company operates, (5) changes in worldwide tax rates or tax benefits from domestic and international operations, including the matters described in Note 4- Uncertainty in Income Taxes- to the Consolidated Financial Statements in the Company's Form 10-Q report for the quarter ended June 30, 2008, (6) exposure to litigation, including product liability claims, (7) changes in research funding and the success of research and development activities, (8) the ability to maintain adequate quality standards, (9) reliance on third party package delivery services, (10) the impact of acquisitions and success in integrating and obtaining projected results from the acquisitions, (11) other changes in the business environment in which the Company operates, and (12) the outcome of the matters described in Note 13 - Contingent Liabilities and Commitments - to the Consolidated Financial Statements in the Company's Form 10-Q report for the quarter ended June 30, 2008. A further discussion of the Company's risk factors can be found in Item 1A of the Company's Form 10-K report for the year ended December 31, 2007. The Company does not undertake any obligation to update these forward- looking statements.

SIGMA-ALDRICH CORPORATION

Consolidated Statements of Income (Unaudited)

(in millions except per share amounts)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Net sales $540.6 $503.2 $1,690.9 $1,506.6

Cost of products sold 262.7 247.3 825.9
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
2. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
3. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in Peer-Reviewed Video Journal JoVE
4. Sigma-Aldrich(R) Becomes First Life Science Company to Publish in PubMeds Peer-Reviewed Video Journal JoVE
5. Sigma-Aldrich to Present at the UBS 2008 Global Life Sciences Conference on September 24, 2008
6. Sigma-Aldrich Launches Breakthrough Genome-Editing Tools
7. Sigma-Aldrich Signs Exclusive Agreement With IsoSciences, LLC, to Distribute Isotopically Labeled Bioactive Compounds
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Sigma-Aldrich (Nasdaq: SIAL) Reports 16.7% Gain in Q2 2008 Diluted EPS. Q2 2008 Sales Rise 14.4%. 2008 Diluted EPS Forecast Raised $.05 to $2.62-$2.72.
10. Sigma-Aldrich Corporations 2nd Quarter 2008 Earnings Conference Call
11. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
(Date:7/24/2014)... Although most natural and synthetic processes prefer to ... potential or energyit is within the realm of ... experience constant changes in energy and phases, such ... These conditions allow humans to regulate their body ... rumble with seismic activity. , But even ...
(Date:7/24/2014)... Your cell phone may stay charged ... storage capacity. , New research indicates that lithium-ion ... at Lawrence Livermore National Laboratory and ... components will perform as electrodes. , The growing ... for higher-performance batteries. Several key characteristics of lithium-ion ...
(Date:7/24/2014)... Three companies from the angelMD network ... C Competition. Out of 700 competition entrants, Chiron Health, ... semi-final round. In this round twenty teams are invited ... with mentoring from thought-leaders and medical entrepreneurs from all ... angelMD commitment to the Livestrong vision around the Big ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... , MURRIETA, Calif., Aug. 27 Despite ... of its US operations. Copan Diagnostics, Inc. is undertaking a ... and additional medical device manufacturing operations to its facility in ... molding machinery and filling and packing equipment to expand Copan,s ...
... , GAITHERSBURG, Md., Aug. 27 GenVec, ... into a purchase agreement with a single institutional investor for the sale ... shares of its common stock. The shares of common stock and ... stock and 0.50 warrants to purchase one share of common stock at ...
... Elbit Imaging Ltd.,("EMI" or the "Company") (NASDAQ: EMITF ... the Page" of Series B Notes of the Company,that the interest ... August 21, 2009 and ending on February 20, 2010 is 1.723125%. ... The Activities of Elbit Imaging Ltd. are divided ...
Cached Biology Technology:Copan Announces Multimillion Expansion for US Pipet Manufacturing Operations 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes 2Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes 3
(Date:7/25/2014)... -- The routine use of a molecular testing ... of performing the correct initial surgery for patients ... the University of Pittsburgh Cancer Institute (UPCI), partner ... UPMC/UPCI Multidisciplinary Thyroid Center and other diagnostic testing ... correct initial surgery by 30 percent, according to ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... disturbance has different effects on different species of ... Universities of Bristol and Exeter which tested fish ... to a flying seagull predator model when exposed ... in European minnows. , Lead author Dr ... said: "Noise levels in many aquatic environments have ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... , During heavy rain, the lid of Nepenthes ... that seek shelter on its underside directly into the ... published today, Wednesday 13 June, in the journal ... insects as a source of nutrients, enabling them to ...
... unfathomable only a few years ago are reality today ... the acquisition of next-generation sequencing technology on the Texas ... of the service. "As we move into the ... in history," said Dr. Charles Johnson, director of the ...
... wide range of diseases and uncover fundamental processes that lead ... for biomedical science. A number of hurdles, both scientific and ... of using these special cells to treat heart disease, diabetes, ... June 13 in Nature , scientists at the Salk ...
Cached Biology News:Pitcher plant uses rain drops to capture prey 2Next-generation sequencing technology opens doors to discoveries 2'Magical state' of embryonic stem cells may help overcome hurdles to therapeutics 2'Magical state' of embryonic stem cells may help overcome hurdles to therapeutics 3
BOND ELUT MATRIX-C18, 25 mg ...
Terrific Broth, 1 kg. Mixture of casein peptone, yeast extract, K2HPO4, and KH2PO4.Used at 47 g/l for E. coli growth with higher cell densities. Category: Nucleotides & Enzymes & Biochemicals, Ultrap...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Human Legumain Affinity Purified Polyclonal Ab...
Biology Products: